Moving Life Science Innovations along the path
From Discovery To Development To Delivery

OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.

OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.

Arizona’s bioscience industry is growing rapidly and reached more than 36,000 jobs spanning 2,912 business establishments in 2021. Industry employment has grown by nearly 22 percent since 2018—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted $602 million in R&D activities in bioscience-related fields in 2020, fueled in part by steadily increasing NIH awards to Arizona institutions since 2018. Venture capital investments in Arizona bioscience companies increased significantly in 2021, and during the 2018-21 period totaled $565 million. Arizona inventors have been awarded 2,283 bioscience related patents since 2018, among the second quintile of states in patent activity. Read the Report: AZ-BIO2022 - state profile

IN THE LOOP

AZBio In The Loop is your opportunity to stay up to date on what is happening across Arizona's Life Science and Healthcare Community.

Subscribe

AZBio Members Are Making LIFE Better

AZBio Members discover, develop, and deliver life-saving and life-changing innovations.

Premiere Supporters

Leadership Supporters

Sustaining Members

Get Connected With Arizona's Bioindustry

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.  

AZBio  Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector.  As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.

AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.

Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.

Success Stories – Good News from Arizona’s BioIndustry

BIO Shares Member Perspectives on the use of Real World Evidence

As policy makers and regulators consider how best to incorporate the use of of real-world evidence (RWE) and real-world data (RWD) for changes to the label of an approved product, The Biotechnology Innovation Organization (BIO) has prepared a white paper to offer the perspectives of BIO member companies.

Report Highlights Best Practices in Bioscience Economic Development

Every two years, the Biotechnology Innovation Organization (BIO) publishes a biennial BIO Economic Development Best Practices Report that  catalogs state and regional economic development initiatives.  The best practice examples contained within this report highlight the critical facets that foster high-performing industry and the long-term success it has maintained. The report reaffirms that successful industry development […]

Master of the immune system: Myxoma virus could solve long-standing medical conundrums

 Virus: friend or foe?  Viruses are likely the most abundant biological entities on Earth – they inhabit every ecosystem, and thus have shaped the evolution of most species. But we have been conditioned to believe that viruses only pose a threat to life. Until recently, viruses were only thought to be infectious agents that exist and […]

AbbVie Announces Plans to Acquire Allergan for $63 Billion

On June 25, 2019, AbbVie Inc. and Allergan announced that the companies have entered into a definitive transaction agreement under which AbbVie will acquire Allergan in a cash and stock transaction for a transaction equity value of approximately $63 billion, based on the closing price of AbbVie’s common stock of $78.45 on June 24, 2019.

AZBio Builds Relationships With Partners Across The Country

Partner Opportunities for AZBio Members

  • Nominate by May 24th - Click to learn more.